The question I have at this point is regarding the
Post# of 30028
Posted On: 08/02/2014 8:54:26 AM
The question I have at this point is regarding the disconnect between how the market/average AMBS investor views the latest news compared to how AMBS/scientific community/pharma industry views it.
Sounds as though people in attendance at the Summit thought the LymPro news/Arendts presentation p16 was a major breakthrough/success.
If this is the case and I'm not doubting it at all, when will it translate into layman's terms so that the market understands it in such a way that equals consistent and stable pps growth?
I know the penny pumps and mm's played a big part in the last two weeks, so I am just focusing on the science. We need revenue (at least guidance) and a partnership for explosive pps growth.
I agree that the small sample size accomplishes what is needed to commercialize for CLIA and larger tests/everyday use is needed on the way to FDA approval. But as long as pharma saw what they needed to see to adopt LymPro for future/ongoing clinical trials, than that should be enough to get LymPro sales off the ground in the near term.
The next 4 weeks are critical for near term pps growth (but not necessarily for the long term). Revenue guidance, the final release of all the site data and partnership news are still what we need to hear and hopefully these will all come to pass before the end of summer.
Sounds as though people in attendance at the Summit thought the LymPro news/Arendts presentation p16 was a major breakthrough/success.
If this is the case and I'm not doubting it at all, when will it translate into layman's terms so that the market understands it in such a way that equals consistent and stable pps growth?
I know the penny pumps and mm's played a big part in the last two weeks, so I am just focusing on the science. We need revenue (at least guidance) and a partnership for explosive pps growth.
I agree that the small sample size accomplishes what is needed to commercialize for CLIA and larger tests/everyday use is needed on the way to FDA approval. But as long as pharma saw what they needed to see to adopt LymPro for future/ongoing clinical trials, than that should be enough to get LymPro sales off the ground in the near term.
The next 4 weeks are critical for near term pps growth (but not necessarily for the long term). Revenue guidance, the final release of all the site data and partnership news are still what we need to hear and hopefully these will all come to pass before the end of summer.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼